How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Jean I. Liu, insider at Seagen

Jean I. Liu Insider Information

EVP of Seagen
With more than 20 years of experience in the biotechnology industry, Jean holds deep expertise in legal and business leadership. She oversees all aspects of the legal, compliance, and intellectual property functions at Seagen and serves as Corporate Secretary, advising on strategic matters. 

Previously, Jean was the Vice President of General Counsel at Halozyme Therapeutics and the Chief Legal Officer and Corporate Secretary at Durect Corporation. Earlier in her career, Jean was an attorney at Pillsbury, Madison & Sutro (now Pillsbury Winthrop) and Venture Law Group, where she advised early-stage companies on technology transfer, licensing, patents, and copyright and trademark litigation. 

Jean holds a J.D. from Columbia University, where she was a Harlan Fiske Stone Scholar. She also earned an M.S. in Biology from Stanford University and a B.S. in Cellular and Molecular Biology with highest distinction from the University of Michigan. She serves as a member of the board of directors for Connect Biopharma Holdings Ltd.

What is Jean I. Liu's net worth?

The estimated net worth of Jean I. Liu is at least $10.61 million as of April 20th, 2022. Ms. Liu owns 75,946 shares of Seagen stock worth more than $10,605,099 as of May 22nd. This net worth evaluation does not reflect any other investments that Ms. Liu may own. Additionally, Ms. Liu receives a salary of $1,110,000.00 as EVP at Seagen. Learn More about Jean I. Liu's net worth.

How old is Jean I. Liu?

Ms. Liu is currently 54 years old. There are 5 older executives and no younger executives at Seagen. The oldest executive at Seagen is Dr. Roger D. Dansey M.D., Chief Medical Officer, who is 66 years old. Learn More on Jean I. Liu's age.

What is Jean I. Liu's salary?

As the EVP of Seagen Inc., Ms. Liu earned a total compensation package of $3,913,724.00 in 2020. Ms. Liu earned a salary of $546,125.00, stock awards of $1,777,282.00, options awards of $1,172,990.00, non-equity compensation of $400,200.00, and other compensation of $17,127.00.There are 3 executives that earn more than Ms. Liu. The highest earning executive at Seagen is Dr. Clay B. Siegall Ph.D., Co-Founder, Chairman, Pres & CEO, who commands a salary of $3,090,000.00 per year. Learn More on Jean I. Liu's salary.

How do I contact Jean I. Liu?

The corporate mailing address for Ms. Liu and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected] Learn More on Jean I. Liu's contact information.

Has Jean I. Liu been buying or selling shares of Seagen?

Jean I. Liu has not been actively trading shares of Seagen during the last quarter. Learn More on Jean I. Liu's trading history.

Who are Seagen's active insiders?

Seagen's insider roster includes Roger Dansey (Insider), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Are insiders buying or selling shares of Seagen?

In the last twelve months, insiders at the biotechnology company sold shares 45 times. They sold a total of 812,757 shares worth more than $125,352,066.18. The most recent insider tranaction occured on May, 16th when EVP Charles R Romp sold 333 shares worth more than $44,691.93. Insiders at Seagen own 27.3 % of the company. Learn More about insider trades at Seagen.

Information on this page was last updated on 5/16/2022.

Jean I. Liu Insider Trading History at Seagen

See Full Table

Jean I. Liu Buying and Selling Activity at Seagen

This chart shows Jean I. Liu's buying and selling at Seagen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Seagen Company Overview

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $139.64
Low: $136.11
High: $144.46

50 Day Range

MA: $139.37
Low: $108.81
High: $156.12

2 Week Range

Now: $139.64
Low: $105.43
High: $192.79


1,692,560 shs

Average Volume

1,329,499 shs

Market Capitalization

$25.70 billion

P/E Ratio


Dividend Yield



Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.